Compare · AMGN vs LXEO
AMGN vs LXEO
Side-by-side comparison of Amgen Inc. (AMGN) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $239.09B, about 568.0x LXEO ($420.9M).
- Over the past year, AMGN is up 52.8% and LXEO is up 5.1% - AMGN leads by 47.7 points.
- AMGN has been more active in the news (18 items in the past 4 weeks vs 12 for LXEO).
- AMGN has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- Amgen Inc.
- Lexeo Therapeutics Inc.
- Price
- -
- -
- Market cap
- $239.09B
- $420.9M
- 1M return
- +17.61%
- +14.29%
- 1Y return
- +52.83%
- +5.13%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2023
- News (4w)
- 18
- 12
- Recent ratings
- 25
- 11
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- SVP, Business Development Khosla Rachna exercised 1,252 shares at a strike of $162.60 and sold $1,346,499 worth of shares (3,252 units at $414.05), decreasing direct ownership by 24% to 6,404 units (SEC Form 4) to satisfy tax liability
- VP, Finance & CAO Busch Matthew C. was granted 730 shares, increasing direct ownership by 17% to 5,080 units (SEC Form 4)
- Director Ishrak Omar was granted 85 shares, increasing direct ownership by 1% to 7,486 units (SEC Form 4)
- Director Holley Charles M was granted 103 shares, increasing direct ownership by 0.80% to 12,990 units (SEC Form 4)
- Director Drake Michael V was granted 64 shares, increasing direct ownership by 1% to 5,876 units (SEC Form 4)
- SVP, Human Resources Miller Derek exercised 3,890 shares at a strike of $169.56 and sold $1,565,898 worth of shares (3,890 units at $402.54) (SEC Form 4) (tax liability)
- SVP & CCO Grygiel Nancy A. exercised 2,970 shares at a strike of $177.41 and sold $1,194,415 worth of shares (2,970 units at $402.16) (SEC Form 4) (for withholding tax)
- Truist reiterated coverage on Amgen with a new price target
- Oppenheimer reiterated coverage on Amgen with a new price target
- Morgan Stanley reiterated coverage on Amgen with a new price target
Latest LXEO
- Chief Financial Officer Tamayo Louis Edward sold $20,203 worth of shares (4,117 units at $4.91), decreasing direct ownership by 4% to 92,907 units (SEC Form 4) (tax withholding)
- Chief Executive Officer Townsend Richard Nolan sold $16,562 worth of shares (3,345 units at $4.95), decreasing direct ownership by 0.89% to 374,472 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Otero Jose Manuel sold $6,464 worth of shares (1,304 units at $4.96), decreasing direct ownership by 0.95% to 136,178 units (SEC Form 4) (for tax liability)
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Lexeo Therapeutics Inc.
- SEC Form 10-Q filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights